High Court Stays Mum On Teva MS Drug Patent Suit

Law360, New York (March 24, 2014, 7:18 PM EDT) -- The U.S. Supreme Court on Monday took no action for a second time in a patent case over Teva Pharmaceuticals USA Inc.'s lucrative multiple sclerosis drug Copaxone, as the clock ticks toward a possible May launch for planned generic versions of the drug.

Teva is appealing a July ruling by the Federal Circuit invalidating several patents covering the drug, which had worldwide sales of $4.3 billion in 2013, and clearing the way for generic versions. The high court was slated to discuss the case at its...
To view the full article, register now.